Teva schizophrenia drug Phase III results excite analysts

Teva  credit: Cineberg/Shutterstock
Teva credit: Cineberg/Shutterstock

Evercore ISI analyst Umer Raffat believes that sales could amount to more than $1 billion annually.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) saw its share price jump 12.8% yesterday, amid high trading volume, to a five-year high. The share price of $15.74 gave a market cap of $17.8 billion, after the company reported first quarter results of $3.81 billion revenue, a GAAP net loss of $139 million and a non-GAAP net profit of $548 million.

Investors liked the fact that Teva reaffirmed its annual outlook and beat the revenue guidance for the quarter due to better than expected sales in the US generics market. The share surged even though earnings per share was lower than analysts' expectations.

But what particularly enthused the market was the positive Phase III clinical trial results of Olanzapine LAI, which Teva is developing with Medincell, and which is injected once a month for the treatment of schizophrenia. Teva CEO Richard Francis said that the trial had met its end points and there was a good likelihood that it would allow long-term effective treatment for schizophrenia, without PDSS side-effects.

If the drug reaches the market it could significantly contribute to Teva's results. Evercore ISI analyst Umer Raffat believes that sales could amount to more than $1 billion annually, which would enhance Teva's EBITDA. He says that Teva's story today is significantly different than several years ago.

UBS believes that annual sales of Olanzapine could reach $875 million by 2030. The Swiss bank's analysts' give a "Buy" recommendation for Teva's share and a price target of $19, a 20.7% upside on the company's current share price. UBS sees Teva's 2024 revenue reaching $16.1 billion with EBITDA of $4.9 billion, higher than the analysts' consensus and in the middle range of Teva's own outlook.

Jefferies gives Teva a target price of $17, an 8% upside for the Israeli pharmaceutical company, and a "Buy" recommendation. Jefferies' analysts think that Teva's share is undervalued and its current price attributes little credit to its product pipeline, probably due to Teva's history in recent years. "We think the market has not fully digested Teva's change in DNA," they write. "We believe that today's announcement (about the trial results) and further announcements in the future about the product pipeline can reflect a change."

Leader Capital Markets yesterday raised the price target for Teva from $16 to $18 (14.4% higher than the current price) with an "Outperform" recommendation. According to Leader research department director Sabina Levy, Teva's revenue in the first quarter was higher than expected, thanks among other things to the strong performance of the generics business and growth of about 8% in the US, and in addition, Teva presented higher than expected revenue from the sale of branded drug Austedo.

Published by Globes, Israel business news - en.globes.co.il - on May 9, 2024.

© Copyright of Globes Publisher Itonut (1983) Ltd., 2024.

Teva  credit: Cineberg/Shutterstock
Teva credit: Cineberg/Shutterstock
Wizz Air  credit: PR Wizz Air poaches two Ryanair routes

In Ryanair's continued absence from Israel, the Hungarian low-cost airline has announced flights to Venice and Thessaloniki.

Scott Russell  credit: Nice Nice rises then plunges on Q2 results

Nice beat analysts' estimates and raised its profit guidance, and its share price jumped, but it is now down by more than 7%.

Combatica simulated training credit: Combatica Defense training company Combatica opens gaming park

The Israeli defense tech company is set to inaugurate its first gaming park in Uganda with a platform based on metaverse glasses.

Israel Discount Bank branch  credit: Shutterstock Discount Bank reports higher profit, to speed up ICC-CAL sale

The bank reported NIS 1.1 billion profit in the second quarter of 2025, up 7% from the corresponding quarter of 2024.

Moshe Larry  credit: PR Mizrahi Tefahot to pay controlling shareholders NIS 300m dividend

The bank reported NIS 1.453 billion net profit in the second quarter of 2025, unchanged from the corresponding quarter but the dividend has been pushed up to 50% of profit.

Evolution credit: Shutterstock Black Cube: Evolution allowed gambling in banned countries

Israeli private intelligence agency has submitted a report on the matter to the New Jersey Supreme Court.

Wix campus  credit: Eyal Izhar Wix enters banking as AI threatens core business

Wix is introducing current banking accounts and loans for small businesses in collaboration with Israeli fintech company Unit.

Ribbon cutting for Haifa airport's Layam duty free store credit: Rami Chelouche Duty free store opens as Haifa airport tries to take off

Teddy Sagi's Layam has opened a 200 square meter duty free store, which offers practically all the tax free goods available at Ben Gurion airport but without the long lines to pay.

Tel Aviv credit: Shutterstock Tel Aviv home prices falling sharply

The data from property websites and anecdotes from real estate agents show a market in decline.

Amit Shaked credit: Tomer Lesher Rubrik launches Agent Rewind to undo AI errors

Agent Rewind was developed with the assistance of Rubrik's Israel development center.

Israeli co Nasus Pharma completes Wall Street IPO

The Tel Aviv-based company develops powder-based Intranasal specialized treatments.

Homes for rent credit: Eyal Izhar Investors shunning Israel's homes market

High interest rates, high taxes and home price falls are driving investors away from the home market, the Ministry of Finance chief economist reports.

Appcharge team credit: PR Mobile games sales platform Appcharge raises $58m

The Israeli company has developed a direct-to-consumer (DTC) platform for mobile game publishers to maximize profits through owning player relationships.

Yadin Antebi  credit: Jonathan Bloom Hapoalim posts NIS 2.5b profit, declares 50% dividend

Annualized return on equity was high at 16.7%, up from 16.4% in the corresponding quarter of 2024.

Bank Leumi CEO Hanan Friedman  credit: Oren Dai Leumi posts NIS 2.6b profit, declares 50% dividend

Bank Leumi recorded an annualized return on equity for the second quarter of 16.2%, up from 15.9% in the second quarter of 2024.

Bezhalel Machlis  credit: Assaf Shilo/Israel Sun $1.6b European order swells Elbit Systems' huge backlog

The Israeli defense company reported an orders backlog of $23.8 billion at the end of the second quarter.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018